Thiazolidinedione anti-cancer activity: Is inhibition of microtubule assembly implicated?

Medical Hypotheses

Volumn 68, Issue 2, 2007, Pages 343-346

  Russu, Wade A ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 O METHYLFUNICONE; ANGIOGENESIS INHIBITOR; BLOCKING AGENT; COLCHICINE; COPTISINE; CYTOCHALASIN; ELEUTHEROBIN; EPOTHILONE A; EPOTHILONE DERIVATIVE; LATRUNCULIN A; NAVELBINE; NOCODAZOLE; PACLITAXEL; PODOPHYLLOTOXIN; RHIZOXIN; ROSIGLITAZONE; SARCODICTYIN A; TUBULIN; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACTIN POLYMERIZATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MOTILITY; CHEMICAL STRUCTURE; DRUG INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HYPOTHESIS; ISOTHERMAL TITRATION CALORIMETRY; MICROTUBULE ASSEMBLY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SCIENTIFIC LITERATURE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CELL CYCLE; HUMANS; MICROTUBULES; MODELS, BIOLOGICAL; THIAZOLIDINEDIONES;

EID: 33845283851     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.06.054     Document Type: Article

References (32)

1. Davis S.N. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Brunton L.L., Lazo J.S., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. (2006), McGraw-Hill, New York 1613-1645
2. Spiegelman B.M. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 47 (1998) 507-514
3. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 28 (2005) 1922-1928
4. Langreth R., and Sharpe R. Warner-Lambert diabetes drug set to be reviewed by FDA panel. Wall Street J 18 January (1999) B7
5. Delea T.E. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26 (2003) 2983-2989
6. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use: fluid retention, and conjestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003) 2941
7. Curtis F.R. What is the future of thiazolidinediones (TZDs) after market introduction of inhaled insulin?. J Manag Care Pharm 12 (2006) 169-172
8. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferators-activated receptor gamma agonists. Lancet Oncol 5 (2004) 419-429
9. Burnstein H.J., Demetri G.D., Mueller E., Sarraf P., Spiegelman B.M., and Winter E.P. Use of peroxisome proliferators-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat 79 (2003) 391-397
10. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., and Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89 (2003) 1409-1412
11. Palakurthi S.S., Aktas H., Grubissich L.M., Mortensen R.M., and Halperin J.A. Anticancer effects of thiazolidinediones are independent of peroxizome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61 (2001) 6213-6218
12. Abe A., Kiriyama Y., Hirano M., et al. Troglitazone suppresses cell growth of KU812 cells independently of PPARγ. Eur J Pharmacol 436 (2002) 7-13
13. Dubois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., and Lazar M.A. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19 (1998) 49-53
14. Seargent J.M., Yates E.A., and Gill J.H. GW9662, a potent antagonist of PPARγ, inhibits growth of breast cancer tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol 143 (2004) 933-937
15. He G., Thuillier P., and Fischer S.M. Troglitazone Inhibits Cyclin D1 Expression and Cell Cycling Independently of PPARg in Normal Mouse Skin Keratinocytes. J Invest Dermatol 123 (2004) 1110-1119
16. Artwohl M., Furnsinn C., Waldhousl W., et al. Thiazolidinediones inhibit proliferation of microvascular cells by a PPARg independent mechanism. Diabetologia 48 (2005) 586-594
17. Sheu W.H.-H., Ou H.-C., Chou F.-P., Lin T.-M., and Yang C.-H. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci 78 (2006) 1520-1528
18. Tanabe H., Suzuki H., Mizukami H., and Inoue M. Double blockade of cell cycle progression by coptisine in vascular smooth muscle cells. Biochem Pharmacol 70 (2005) 1176-1184
19. Buommino E., Nicoletti R., Gaeta G.M., et al. 3-O-Methylfunicone, a secondary metabolite produced by Penicillium pinophilum, induces growth arrest and apoptosis in HeLa cells. Cell Prolif 37 (2004) 413-426
20. Chen J.-G., and Horwitz S.B. Differential Mitotic Responses to Microtubule-stabilizing and -destabilizing Drugs. Cancer Res 62 (2002) 1935-1938
21. Aubin J.E., Osborn M., and Weber K. Inhibition of cytokinesis and altered contractile ring morphology induced by cytochalasins in synchronized PtK2 cells. Exp Cell Res 136 (1981) 63-79
22. Lohez O.D., Reynaud C., Borel F., Andreassen P.R., and Margolis R.L. Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. J Cell Biol 161 (2003) 67-77
23. Huang S., and Ingber D.E. A Discrete Cell Cycle Checkpoint in Late G1 That Is Cytoskeleton-Dependent and MAP Kinase (Erk)-Independent. Exp Cell Res 275 (2002) 255-264
24. Panigrahy D., Singer S., Shen L.Q., et al. PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin, Invest 110 (2002) 923-932
25. Hayot C., Farinelle S., Decker R., et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 21 (2002) 417-425
26. El Sayed K.A., Youssef D.T.A., and Marchetti D. Bioactive Natural and Semisynthetic Latrunculins. J Nat Prod 69 (2006) 219-223
27. Enomoto T. Microtubule Disruption Induces the Formation of Actin Stress Fibers and Focal Adhesions in Cultured Cells: Possible Involvement of the Rho Signal Cascade. Cell Struct Funct 21 (1996) 317-326
28. Waterman-Storer C.M., and Salmon E.D. Positive feedback interactions between microtubule and actin dynamics during cell motility. Curr Opin Cell Biol 11 (1999) 61-67
29. Islam M.N., and Iskander M.N. Microtubulin Binding Sites as Target for Developing Anticancer Agents. Mini-Revs Med Chem 4 (2004) 1077-1104
30. Nguyen T.L., McGrath C., Hermone A.R., et al. A Common Pharmacophore for a Diverse Set of Colchicine Site Inhibitors Using a Structure-Based Approch. J Med Chem 48 (2005) 6107-6116
31. Grosios K., Holwell S.E., McGrown A.T., Pettit G.R., and Bibby M.C. In ivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81 (1999) 1318-1327
32. Gueritte F., and Fahy J. The Vinca Alkaloids. In: Cragg G.M., Kingston D.G.I., and Newman D.J. (Eds). Anticancer Agents from Natural Products (2005), Taylor & Francis, New York 123-135